572 related articles for article (PubMed ID: 20373869)
1. Fatty acid synthase as a potential therapeutic target in cancer.
Flavin R; Peluso S; Nguyen PL; Loda M
Future Oncol; 2010 Apr; 6(4):551-62. PubMed ID: 20373869
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological inhibitors of Fatty Acid Synthase (FASN)--catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer agents?
Lupu R; Menendez JA
Curr Pharm Biotechnol; 2006 Dec; 7(6):483-93. PubMed ID: 17168665
[TBL] [Abstract][Full Text] [Related]
3. Fatty acid synthase inhibitors: new directions for oncology.
Kridel SJ; Lowther WT; Pemble CW
Expert Opin Investig Drugs; 2007 Nov; 16(11):1817-29. PubMed ID: 17970640
[TBL] [Abstract][Full Text] [Related]
4. Recent Advances in the Development of Fatty Acid Synthase Inhibitors as Anticancer Agents.
Singh S; Karthikeyan C; Moorthy NSHN
Mini Rev Med Chem; 2020; 20(18):1820-1837. PubMed ID: 32781957
[TBL] [Abstract][Full Text] [Related]
5. Fatty acid synthase overexpression: target for therapy and reversal of chemoresistance in ovarian cancer.
Bauerschlag DO; Maass N; Leonhardt P; Verburg FA; Pecks U; Zeppernick F; Morgenroth A; Mottaghy FM; Tolba R; Meinhold-Heerlein I; Bräutigam K
J Transl Med; 2015 May; 13():146. PubMed ID: 25947066
[TBL] [Abstract][Full Text] [Related]
6. Fatty Acid Synthase: An Emerging Target in Cancer.
Fhu CW; Ali A
Molecules; 2020 Aug; 25(17):. PubMed ID: 32872164
[TBL] [Abstract][Full Text] [Related]
7. Fatty acid synthase inhibitors induce apoptosis in non-tumorigenic melan-a cells associated with inhibition of mitochondrial respiration.
Rossato FA; Zecchin KG; La Guardia PG; Ortega RM; Alberici LC; Costa RA; Catharino RR; Graner E; Castilho RF; Vercesi AE
PLoS One; 2014; 9(6):e101060. PubMed ID: 24964211
[TBL] [Abstract][Full Text] [Related]
8. A novel small-molecule fatty acid synthase inhibitor with antitumor activity by cell cycle arrest and cell division inhibition.
Qu H; Shan K; Tang C; Cui G; Fu G; Qi Y; Cui J; Li J; Wang R; Feng N; Chen YQ
Eur J Med Chem; 2021 Jul; 219():113407. PubMed ID: 33901805
[TBL] [Abstract][Full Text] [Related]
9. Blockade of fatty acid synthase induces ubiquitination and degradation of phosphoinositide-3-kinase signaling proteins in ovarian cancer.
Tomek K; Wagner R; Varga F; Singer CF; Karlic H; Grunt TW
Mol Cancer Res; 2011 Dec; 9(12):1767-79. PubMed ID: 21970855
[TBL] [Abstract][Full Text] [Related]
10. Targeting fatty acid synthase in breast and endometrial cancer: An alternative to selective estrogen receptor modulators?
Lupu R; Menendez JA
Endocrinology; 2006 Sep; 147(9):4056-66. PubMed ID: 16809439
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory effect of emodin on fatty acid synthase, colon cancer proliferation and apoptosis.
Lee KH; Lee MS; Cha EY; Sul JY; Lee JS; Kim JS; Park JB; Kim JY
Mol Med Rep; 2017 Apr; 15(4):2163-2173. PubMed ID: 28260110
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of fatty acid synthase in human gliomas correlates with the WHO tumor grade and inhibition with Orlistat reduces cell viability and triggers apoptosis.
Grube S; Dünisch P; Freitag D; Klausnitzer M; Sakr Y; Walter J; Kalff R; Ewald C
J Neurooncol; 2014 Jun; 118(2):277-287. PubMed ID: 24789255
[TBL] [Abstract][Full Text] [Related]
13. An Inhibitor of Fatty Acid Synthase Thioesterase Domain with Improved Cytotoxicity against Breast Cancer Cells and Stability in Plasma.
Lupien LE; Dunkley EM; Maloy MJ; Lehner IB; Foisey MG; Ouellette ME; Lewis LD; Pooler DB; Kinlaw WB; Baures PW
J Pharmacol Exp Ther; 2019 Oct; 371(1):171-185. PubMed ID: 31300609
[TBL] [Abstract][Full Text] [Related]
14. Molecular Pathways: Fatty Acid Synthase.
Jones SF; Infante JR
Clin Cancer Res; 2015 Dec; 21(24):5434-8. PubMed ID: 26519059
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple-Negative Breast Cancer.
Giró-Perafita A; Palomeras S; Lum DH; Blancafort A; Viñas G; Oliveras G; Pérez-Bueno F; Sarrats A; Welm AL; Puig T
Clin Cancer Res; 2016 Sep; 22(18):4687-97. PubMed ID: 27106068
[TBL] [Abstract][Full Text] [Related]
16. Fatty acid synthase inhibition results in a magnetic resonance-detectable drop in phosphocholine.
Ross J; Najjar AM; Sankaranarayanapillai M; Tong WP; Kaluarachchi K; Ronen SM
Mol Cancer Ther; 2008 Aug; 7(8):2556-65. PubMed ID: 18723500
[TBL] [Abstract][Full Text] [Related]
17. FASN Inhibitors Enhance Bestatin-Related Tumor Cell Apoptosis Through Upregulating PEPT1.
Ni J; Shang Y; Wang WD; Wang C; Wang AM; Li GJ; Chen SZ
Curr Mol Pharmacol; 2023; 16(7):771-786. PubMed ID: 36411574
[TBL] [Abstract][Full Text] [Related]
18. Anti-cancer drugs targeting fatty acid synthase (FAS).
Pandey PR; Liu W; Xing F; Fukuda K; Watabe K
Recent Pat Anticancer Drug Discov; 2012 May; 7(2):185-97. PubMed ID: 22338595
[TBL] [Abstract][Full Text] [Related]
19. Fatty acid synthase inhibition engages a novel caspase-2 regulatory mechanism to induce ovarian cancer cell death.
Yang CS; Matsuura K; Huang NJ; Robeson AC; Huang B; Zhang L; Kornbluth S
Oncogene; 2015 Jun; 34(25):3264-72. PubMed ID: 25151963
[TBL] [Abstract][Full Text] [Related]
20. Crosstalk between osteoprotegerin (OPG), fatty acid synthase (FASN) and, cycloxygenase-2 (COX-2) in breast cancer: implications in carcinogenesis.
Goswami S; Sharma-Walia N
Oncotarget; 2016 Sep; 7(37):58953-58974. PubMed ID: 27270654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
